Études d'intervention
14 nov 2017
Bénéfice accru pour l'empagliflozine chez les patients diabétiques artériopathes
S. Verma (Canada) - Empagliflozin reduces mortality and hospitalization for heart failure in patients with type 2 diabetes and peripheral artery disease: a sub-analysis of the EMPA-REG OUTCOME trial